1. |
European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol, 2012, 57(1): 167-185.
|
2. |
Liaw YF, Kao JH, Piratvisuth T ,et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int, 2012, 6(3): 531-561.
|
3. |
Li WC, Wang MR, Kong LB, et al. Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials. BMC Infect Dis, 2011, 11: 165.
|
4. |
Huang R, Hao Y, Zhang J, et al. Interferon-alpha plus adefovir combination therapy versus interferon-alpha monotherapy for chronic hepatitis B treatment: A meta-analysis. Hepatol Res, 2013, 43(10): 1040-1051.
|
5. |
Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0[updated March 2011]. Available at: http://handbook.cochrane.org/.
|
6. |
敖飞健, 马为民, 周伯平, 等. 聚乙二醇干扰素-2a、阿德福韦酯单用及联合应用治疗HBeAg阳性慢性乙型肝炎患者的疗效及安全性比较. 中华传染病杂志, 2010, 28(4): 214-217.
|
7. |
丁蔚茅. 长效干扰素联合阿德福韦酯治疗慢性乙型肝炎22例疗效观察. 中国现代药物应用, 2010, 4(22): 164-165.
|
8. |
袁健志. 聚乙二醇干扰素α-2b联合阿德福韦酯与单用聚乙二醇干扰素α-2b治疗HBeAg阳性慢性乙型肝炎48周疗效比较. 汕头: 汕头大学, 2012.
|
9. |
陈海鸥, 刘洪娟, 胡小宣. 阿德福韦酯联合聚乙二醇干扰素-2a治疗的疗效观察. 胃肠病学和肝病学杂志, 2013, 22(5): 456-458.
|
10. |
李文兵, 丁继光, 孙庆丰, 等. 聚乙二醇干扰素-2a与阿德福韦酯联合治疗HBeAg阳性慢性乙型肝炎患者的研究. 中华医院感染学杂志, 2013, 23(6): 1250-1252.
|
11. |
梁江萍, 张祥明, 夏俊, 等. 干扰素联合阿德福韦酯治疗慢性乙型肝炎疗效观察. 中华医院感染学杂志, 2013, 23(14): 3498-3500.
|
12. |
韩思源, 荣光, 王燕. 聚乙二醇干扰素α-2a联合阿德福韦酯治疗HBeAg阳性慢性乙型肝炎疗效观察. 中国实用医药, 2014, 9(20): 1-2.
|
13. |
Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet, 2005, 365(9454): 123-129.
|
14. |
Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med, 2005, 352(26): 2682-2695.
|
15. |
Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBsAg loss after long term follow-up of HBeAg-positive patients treated with peginterferon α-2b. Gastroenterology, 2008, 135(2): 459-467.
|
16. |
陶兴飞, 骆小燕, 楼莲青, 等. 聚乙二醇干扰素a-2a联合拉米夫定治疗HBeAg阳性慢性乙型肝炎疗效观察. 中国微生态学杂志, 2013, 25(11): 1330-1332.
|
17. |
Chan HL, Hui AY, Wong VW ,et al. Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. Hepatology, 2005, 41(6): 1357-1364.
|
18. |
陈思路, 赵彩彦. 乙型肝炎病毒表面抗原清除的相关因素研究进展. 中华临床感染病杂志, 2014, 7(4): 377-381.
|
19. |
Gish RG, Chang TT, Lai CL ,et al. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B. J Viral Hep, 2010, 17(1): 16-22.
|
20. |
Chang TT, Lai CL, Kew KS, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology, 2010, 51(2): 422-430.
|
21. |
Heathcote EJ, Marcellin P, Buti M, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology, 2011, 140(1): 132-143.
|
22. |
Heathcote EJ, Gane EJ, deMan RA, et al. Long term (4 year) efficacy and safety of tenofovir disoproxil fumarate (TDF) treatment in HBeAg-positive patients (HBeAg+) with chronic hepatitis B (Study 103): preliminary results. Hepatology, 2010, 52(S1): 477A.
|